EMA committee recommends orphan drug designation to BioInvent’s BI-1808 to treat cutaneous T-cell lymphoma: Lund, Sweden Tuesday, November 18, 2025, 11:00 Hrs [IST] BioInvent In ...
Karolinska Development AB ( ($SE:KDEV) ) just unveiled an update. Karolinska Development AB’s portfolio company, Umecrine Cognition, has published ...
STOCKHOLM - November 17, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company ...
Xintela (XINT) announces that the last patient has been dosed in the company's clinical Phase I/IIa study with XSTEM® in patients with difficult-to-heal venous leg ulcers. XSTEM, which consists of all ...
LUND, SE / ACCESS Newswire / November 17, 2025 / BioInvent International AB ("BioInvent")(Nasdaq Stockholm: BINV)(STO:BINV), a biotech company focused on the discovery and development of novel and fir ...
LUND, SE / ACCESS Newswire / November 17, 2025 / BioInvent International AB ("BioInvent")(Nasdaq Stockholm: BINV)(STO:BINV), a biotech company focused on the discovery and development of novel and ...
New phase 3 data show meaningful improvement in antibody-negative myasthenia gravis, for which treatment options are limited ...
BioInvent International AB ( ($SE:BINV) ) has issued an announcement. BioInvent International AB announced promising Phase 1 clinical data for its ...
The third quarter 2025 financial results and business update will be discussed during a conference call and webcast presentation today at 1:30 pm CET/8:30 am ET. A webcast of the live call and replay ...
STOCKHOLM, SWEDEN November 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate the ...
Early data from the ADAPT JR trial suggest efgartigimod may benefit adolescents with generalized myasthenia gravis, a rare condition with few effective treatment options.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback